KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 63 days ( -0.633 % )
Last Price $0.151 0 %
High/ Low $0.151 - $0.151 0%
Chg 7 Days N/A $0.151 $0.151
Chg 30 Days N/A $0.151 $0.151
Chg 12 mos -93.23 % $2.23 $0.151
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos -58.21 % Width: 226.30 %
Pred. range - 3 mos $0.151 - $0.151 0 % - 0 %
Pred. range - 12 mos N/A - $0.563 -100.00 % - 272.91 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Buy Jan 10, 2023 - 69 days
Long MA avg 12 mos Sell Sep 13, 2022 - 151 days
Short/Long MA avg 12 mos Sell Aug 08, 2022 - 176 days
Pivot Short Sell Apr 18, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the... CLVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT